BR112018014247A2 - inibição de reação alérgica usando um inibidor il-33 - Google Patents

inibição de reação alérgica usando um inibidor il-33

Info

Publication number
BR112018014247A2
BR112018014247A2 BR112018014247A BR112018014247A BR112018014247A2 BR 112018014247 A2 BR112018014247 A2 BR 112018014247A2 BR 112018014247 A BR112018014247 A BR 112018014247A BR 112018014247 A BR112018014247 A BR 112018014247A BR 112018014247 A2 BR112018014247 A2 BR 112018014247A2
Authority
BR
Brazil
Prior art keywords
inhibitor
allergic reaction
reaction inhibition
mammal
inhibition
Prior art date
Application number
BR112018014247A
Other languages
English (en)
Portuguese (pt)
Inventor
Londei Marco
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of BR112018014247A2 publication Critical patent/BR112018014247A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112018014247A 2016-01-14 2017-01-17 inibição de reação alérgica usando um inibidor il-33 BR112018014247A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278671P 2016-01-14 2016-01-14
PCT/US2017/013818 WO2017124110A1 (en) 2016-01-14 2017-01-17 Inhibition of allergic reaction using an il-33 inhibitor

Publications (1)

Publication Number Publication Date
BR112018014247A2 true BR112018014247A2 (pt) 2018-12-18

Family

ID=59311527

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014247A BR112018014247A2 (pt) 2016-01-14 2017-01-17 inibição de reação alérgica usando um inibidor il-33

Country Status (12)

Country Link
US (1) US20190016795A1 (https=)
EP (1) EP3402521A4 (https=)
JP (1) JP2019508382A (https=)
KR (1) KR20180101533A (https=)
CN (1) CN109475622A (https=)
AU (1) AU2017208099A1 (https=)
BR (1) BR112018014247A2 (https=)
CA (1) CA3011547A1 (https=)
EA (1) EA201891628A1 (https=)
MX (1) MX2018008732A (https=)
SG (2) SG11201805900YA (https=)
WO (1) WO2017124110A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
JP2019516362A (ja) 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
GB201712952D0 (en) * 2017-08-11 2017-09-27 Univ Edinburgh Immunomodulatory agent
EP3694877A1 (en) * 2017-10-09 2020-08-19 AnaptysBio, Inc. Anti-il-33 therapy for atopic dermatitis
WO2019183639A1 (en) * 2018-03-23 2019-09-26 Anaptysbio, Inc. Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
US20230099101A1 (en) * 2020-03-06 2023-03-30 The Regents Of The University Of Michigan Serine protease inhibitors for suppressing or preventing anaphylactic reaction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560530B1 (en) * 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
IE20080331A1 (en) * 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
WO2014152195A1 (en) * 2013-03-15 2014-09-25 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
KR101567758B1 (ko) * 2013-10-17 2015-11-11 인하대학교 산학협력단 항-Siglec-8 항체 또는 항-Siglec-F 항체, 및 항-IL-33 항체를 포함하는 알러지 질환의 예방 또는 치료용 조성물
BR112016013347B1 (pt) * 2013-12-26 2023-12-12 Mitsubishi Tanabe Pharma Corporation Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos
SG11201605580RA (en) * 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)

Also Published As

Publication number Publication date
AU2017208099A1 (en) 2018-08-09
CN109475622A (zh) 2019-03-15
EP3402521A4 (en) 2019-11-20
KR20180101533A (ko) 2018-09-12
JP2019508382A (ja) 2019-03-28
CA3011547A1 (en) 2017-07-20
WO2017124110A1 (en) 2017-07-20
US20190016795A1 (en) 2019-01-17
MX2018008732A (es) 2018-12-06
EA201891628A1 (ru) 2018-12-28
SG10202006699XA (en) 2020-08-28
EP3402521A1 (en) 2018-11-21
SG11201805900YA (en) 2018-08-30

Similar Documents

Publication Publication Date Title
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
KR102609396B9 (ko) Ldha의 발현을 억제하기 위한 방법 및 조성물
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
EA201691421A1 (ru) Гетероарилы и их применение
EP3626699A4 (en) SSAO INHIBITOR
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
MX379270B (es) Composiciones que comprenden cepas bacterianas.
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018004620A2 (pt) moduladores da expressão de kras
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX386418B (es) Composicion acida que comprende una ficocianina.
EA201690987A1 (ru) Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
HUE052642T2 (hu) DOPA dekarboxiláz inhibitor készítmények
AU2017247004A1 (en) Method of treating atherosclerosis
MX374654B (es) Compuestos útiles para inhibir ror-gamma-t.
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
WO2016172417A3 (en) Interactions between ceacam and tim family members

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2653 DE 09-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.